Q-omics provides the consensus-scored MIR4642 profile across patient tissues and cancer cell-line models. MIR4642 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR4642 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, MIR4642 RNA expression shows 6,191 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, HNSC, and STAD as cancer lineages where MIR4642 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4642 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4642 survival associations across molecular data types. MIR4642 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4642 RNA expression–survival associations across cancer types. High MIR4642 expression shows unfavorable associations in KIRC, SKCM, LUSC and STAD, but favorable associations in UCS and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR4642 RNA expression.
This table summarizes MIR4642 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4642. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4642 shows lower tumor expression in KICH and LUAD and higher tumor expression in HNSC, STAD, PRAD and LIHC. The HNSC box plot shows higher MIR4642 RNA expression in tumor versus normal tissue (log2 FC = +0.200, t-test p = .001).
This table shows molecular features associated with MIR4642 in patient tissues and cancer cell lines. In patient samples, MIR4642 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
